Last reviewed · How we verify
NCT04670328
Role of Hematological Parameters in the Stratification of COVID-19 Disease Severity
trial testing not required in Covid19 in 101 participants. Completed in 31 July 2020.
31 July 2020
Quick facts
| Lead sponsor | FMH College of Medicine and Dentistry |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 101 |
| Start date | 1 May 2020 |
| Primary completion | 31 July 2020 |
| Estimated completion | 31 July 2020 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- not required
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
FMH College of Medicine and Dentistry
Who can join
Adults 17 to 75, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The hemostatic abnormalities in COVID-19 are related with disease progression, severity and mortality. The Objective of our study is to evaluate the role of hematological parameters in determination of COVID-19 disease severity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04670328
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of not required
Trials testing the same drug.
- NCT05164640 — Ischemia in Patients With Non-obstructive Disease (INOCA) in Italy INOCA IT Multicenter Registry" · NA · completed
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other FMH College of Medicine and Dentistry trials
Trials by the same sponsor.
- NCT05249803 — "Clinical Characteristics, Comorbidities and Outcome of Critically Sick Patients With COVID-19 · completed
- NCT04730323 — TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience · Phase 4 · completed
- NCT04739410 — Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04670328 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by FMH College of Medicine and Dentistry
- Last refreshed: 17 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04670328.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing